$GILD Company News Lobbyists for insurers, big
Post# of 144503
Posted On: 06/03/2014 10:37:47 AM
$GILD Company News
Lobbyists for insurers, big pharma trade barbs over high drug costs 3:10 p.m. June 2, 2014 - blogs.marketwatch.com
Industry titan UnitedHealth misses boom in sector 10:53 a.m. May 29, 2014 - Russ Britt
Gilead says its drug gives hepatitis C patients more cost-effective cure 5:06 p.m. April 30, 2014 - blogs.marketwatch.com
Why a diverse ETF portfolio is right for these times 6:29 a.m. April 30, 2014 - John Prestbo
Internet, biotech could spawn next Apple: Allianz CIO 7:12 a.m. April 29, 2014 - Barbara Kollmeyer
What Obamacare problems? Aetna results not showing any ill effects 12:34 p.m. April 24, 2014 - blogs.marketwatch.com
U.S. stocks tumble; S&P 500 ends 6-day run 4:46 p.m. April 23, 2014 - Anora Mahmudova
Apple, Facebook stuck in red ahead of earnings 3:02 p.m. April 23, 2014 - Saumya Vaishampayan
U.S. stock futures pause after six-session win streak 8:57 a.m. April 23, 2014 - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. April 23, 2014 - blogs.marketwatch.com
Apple, Facebook, Boeing are stocks to watch 5:30 a.m. April 23, 2014 - Sue Chang
Gilead shares climb; AT&T, Amgen shares fall 5:55 p.m. April 22, 2014 - Myra P. Saefong
Gilead scores big on earnings with new drug, but investors getting wary 5:46 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead earnings buoyed by Hepatitis-C drug 5:04 p.m. April 22, 2014 - Anna Prior
Gilead Sciences shares up 4.5% in after-hours trade 4:35 p.m. April 22, 2014 - Myra P. Saefong
Gilead beats expectations; Sovaldi sales hit $2.3 bln 4:22 p.m. April 22, 2014 - Claudia Assis
Gilead: Hep C drug Sovaldi sells $2.27 billion 4:17 p.m. April 22, 2014 - Claudia Assis
Gilead Sciences Q1 non GAAP EPS $1.48 vs. 48c 4:15 p.m. April 22, 2014 - Claudia Assis
Should doctors care what treatments cost? 4:14 p.m. April 22, 2014 - blogs.marketwatch.com
S&P 500, Nasdaq extend win streak to 6 sessions: Stock market live blog recap 3:56 p.m. April 22, 2014 - blogs.marketwatch.com
Applied Genetic (AGTC) Soars: Stock Up 44.1% - Tale of the Tape 58 min ago - Zacks.com
Gilead CLL drug effective in Phase 2 trial 9:30 a.m. Today - Seeking Alpha
Puma Biotechnology (PBYI) Crumbles: Stock Plunges by 25.3% - Tale of the Tape 8:45 a.m. Today - Zacks.com
Ariad Pharmaceuticals (ARIA) Catches Eye: Stock Up 7.43% - Tale of the Tape 8:44 a.m. Today - Zacks.com
UPDATE: Gilead Reports Updated Phase 2 Results for Investigational GS-9973, Showed 49% Overall Response Rate with Est. Progression-Free Survival Rate at 24 Weeks 70% 7:33 a.m. Today - benzinga.com
Quebec Becomes First Province to Reimburse Sovaldi® for the Treatment of Chronic Hepatitis C 5:59 a.m. Today - CNW Group
Quebec Becomes First Province to Reimburse Sovaldi® for the Treatment of Chronic Hepatitis C 9:20 p.m. June 2, 2014 - CNW Group
Patent infringement suit dismissed 6:30 p.m. June 2, 2014 - Seeking Alpha
Roche Acquires Genia Technologies - Analyst Blog 4:40 p.m. June 2, 2014 - Zacks.com
Merck Presents Positive Trial Results For Cancer Drug 4:12 p.m. June 2, 2014 - Investors Business Daily
Myriad Genetics to Unveil BRACAnalysis, HRD Data - Analyst Blog 3:30 p.m. June 2, 2014 - Zacks.com
Why Vertex Pharmaceuticals Will Likely Climb to New High 1:26 p.m. June 2, 2014 - TheStreet.com
Value Of U.S. Equity Buybacks In May Drops 12:53 p.m. June 2, 2014 - benzinga.com
Encouraging Data on Pharmacyclics/J&J Drug - Analyst Blog 12:10 p.m. June 2, 2014 - Zacks.com
NPS Pharma on Shire's Radar? - Analyst Blog 11:30 a.m. June 2, 2014 - Zacks.com
Stock Market News for June 02, 2014 - Market News 10:06 a.m. June 2, 2014 - Zacks.com
Retrophin (RTRX) Jumps: Stock Adds 13.5% in Session - Tale of the Tape 9:25 a.m. June 2, 2014 - Zacks.com
Allergan Inc. (AGN) in Focus: Stock Rises 5.65% - Tale of the Tape 8:44 a.m. June 2, 2014 - Zacks.com
Analyst Cancer and Biotech Stock Picks From ASCO 7:57 a.m. June 2, 2014 - 247WallSt.com
Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients 7:35 a.m. May 31, 2014 - TheStreet.com
Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia 8:30 a.m. Today - BusinessWire - BZX
Stocks Coverage on Biotech Equities -- Research on Gilead Sciences, ARIAD Pharma, Rexahn Pharma, and Geron 7:10 a.m. May 30, 2014 - PR Newswire - PRF
Clinical Study Results, Schedule of Upcoming Conferences, Dividend Declaration, and Services Agreement - Analyst Notes on Gilead, Quest Diagnostics, Sarepta Therapeutics, Incyte and Centene 5:10 a.m. May 28, 2014 - PR Newswire - PRF
AHF: ‘Negligent Corporate Welfare’ Pushes Gilead to Top of S&P 500 5:40 p.m. May 22, 2014 - BusinessWire - BZX
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF
Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults 5:00 p.m. May 20, 2014 - BusinessWire - BZX
Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology 7:40 a.m. May 20, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the 2014 UBS Healthcare Conference on Tuesday, May 20 5:00 p.m. May 19, 2014 - BusinessWire - BZX
Critical Alerts For Goldman Sachs, Noodles & Company, Starbucks, Gilead Sciences, and Time Warner Cable Released By InvestorsObserver 9:31 a.m. May 14, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14 5:00 p.m. May 13, 2014 - BusinessWire - BZX
Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 4:31 p.m. May 9, 2014 - BusinessWire - BZX
Cancer Diagnostics Partnering Terms and Agreements 5:41 p.m. May 7, 2014 - PR Newswire - PRF
Gilead Announces $5 Billion Share Repurchase Program 5:17 p.m. May 7, 2014 - BusinessWire - BZX
Medivir: a Supplemental New Drug Application Has Been Submitted to the U.S. FDA for Simeprevir in Combination with Sofosbuvir 8:06 a.m. May 7, 2014 - BusinessWire - BZX
Biotech Stocks Review -- Research on Retrophin, Merrimack, Gilead Sciences, and Rexahn Pharma 12:37 p.m. May 6, 2014 - PR Newswire - PRF
BetterInvesting Magazine Releases July Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use 4:15 p.m. May 2, 2014 - PR Newswire - PRF
Parion Sciences Reacquires Rights to Epithelial Sodium Channel Inhibitors 9:00 a.m. April 30, 2014 - PR Newswire - PRF
The World Market for Orphan Drugs 6:59 p.m. April 29, 2014 - PR Newswire - PRF
Critical Alerts For Comcast, Gilead Sciences, Ciena, Adobe Systems, and Celldex Therapeutics Released By InvestorsObserver 9:31 a.m. April 29, 2014 - PR Newswire - PRF
Federal Circuit Rules for Axinn Client Natco Pharma Ltd. in Tamiflu Patent Appeal 1:50 p.m. April 25, 2014 - BusinessWire - BZX
Lobbyists for insurers, big pharma trade barbs over high drug costs 3:10 p.m. June 2, 2014 - blogs.marketwatch.com
Industry titan UnitedHealth misses boom in sector 10:53 a.m. May 29, 2014 - Russ Britt
Gilead says its drug gives hepatitis C patients more cost-effective cure 5:06 p.m. April 30, 2014 - blogs.marketwatch.com
Why a diverse ETF portfolio is right for these times 6:29 a.m. April 30, 2014 - John Prestbo
Internet, biotech could spawn next Apple: Allianz CIO 7:12 a.m. April 29, 2014 - Barbara Kollmeyer
What Obamacare problems? Aetna results not showing any ill effects 12:34 p.m. April 24, 2014 - blogs.marketwatch.com
U.S. stocks tumble; S&P 500 ends 6-day run 4:46 p.m. April 23, 2014 - Anora Mahmudova
Apple, Facebook stuck in red ahead of earnings 3:02 p.m. April 23, 2014 - Saumya Vaishampayan
U.S. stock futures pause after six-session win streak 8:57 a.m. April 23, 2014 - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. April 23, 2014 - blogs.marketwatch.com
Apple, Facebook, Boeing are stocks to watch 5:30 a.m. April 23, 2014 - Sue Chang
Gilead shares climb; AT&T, Amgen shares fall 5:55 p.m. April 22, 2014 - Myra P. Saefong
Gilead scores big on earnings with new drug, but investors getting wary 5:46 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead earnings buoyed by Hepatitis-C drug 5:04 p.m. April 22, 2014 - Anna Prior
Gilead Sciences shares up 4.5% in after-hours trade 4:35 p.m. April 22, 2014 - Myra P. Saefong
Gilead beats expectations; Sovaldi sales hit $2.3 bln 4:22 p.m. April 22, 2014 - Claudia Assis
Gilead: Hep C drug Sovaldi sells $2.27 billion 4:17 p.m. April 22, 2014 - Claudia Assis
Gilead Sciences Q1 non GAAP EPS $1.48 vs. 48c 4:15 p.m. April 22, 2014 - Claudia Assis
Should doctors care what treatments cost? 4:14 p.m. April 22, 2014 - blogs.marketwatch.com
S&P 500, Nasdaq extend win streak to 6 sessions: Stock market live blog recap 3:56 p.m. April 22, 2014 - blogs.marketwatch.com
Applied Genetic (AGTC) Soars: Stock Up 44.1% - Tale of the Tape 58 min ago - Zacks.com
Gilead CLL drug effective in Phase 2 trial 9:30 a.m. Today - Seeking Alpha
Puma Biotechnology (PBYI) Crumbles: Stock Plunges by 25.3% - Tale of the Tape 8:45 a.m. Today - Zacks.com
Ariad Pharmaceuticals (ARIA) Catches Eye: Stock Up 7.43% - Tale of the Tape 8:44 a.m. Today - Zacks.com
UPDATE: Gilead Reports Updated Phase 2 Results for Investigational GS-9973, Showed 49% Overall Response Rate with Est. Progression-Free Survival Rate at 24 Weeks 70% 7:33 a.m. Today - benzinga.com
Quebec Becomes First Province to Reimburse Sovaldi® for the Treatment of Chronic Hepatitis C 5:59 a.m. Today - CNW Group
Quebec Becomes First Province to Reimburse Sovaldi® for the Treatment of Chronic Hepatitis C 9:20 p.m. June 2, 2014 - CNW Group
Patent infringement suit dismissed 6:30 p.m. June 2, 2014 - Seeking Alpha
Roche Acquires Genia Technologies - Analyst Blog 4:40 p.m. June 2, 2014 - Zacks.com
Merck Presents Positive Trial Results For Cancer Drug 4:12 p.m. June 2, 2014 - Investors Business Daily
Myriad Genetics to Unveil BRACAnalysis, HRD Data - Analyst Blog 3:30 p.m. June 2, 2014 - Zacks.com
Why Vertex Pharmaceuticals Will Likely Climb to New High 1:26 p.m. June 2, 2014 - TheStreet.com
Value Of U.S. Equity Buybacks In May Drops 12:53 p.m. June 2, 2014 - benzinga.com
Encouraging Data on Pharmacyclics/J&J Drug - Analyst Blog 12:10 p.m. June 2, 2014 - Zacks.com
NPS Pharma on Shire's Radar? - Analyst Blog 11:30 a.m. June 2, 2014 - Zacks.com
Stock Market News for June 02, 2014 - Market News 10:06 a.m. June 2, 2014 - Zacks.com
Retrophin (RTRX) Jumps: Stock Adds 13.5% in Session - Tale of the Tape 9:25 a.m. June 2, 2014 - Zacks.com
Allergan Inc. (AGN) in Focus: Stock Rises 5.65% - Tale of the Tape 8:44 a.m. June 2, 2014 - Zacks.com
Analyst Cancer and Biotech Stock Picks From ASCO 7:57 a.m. June 2, 2014 - 247WallSt.com
Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients 7:35 a.m. May 31, 2014 - TheStreet.com
Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia 8:30 a.m. Today - BusinessWire - BZX
Stocks Coverage on Biotech Equities -- Research on Gilead Sciences, ARIAD Pharma, Rexahn Pharma, and Geron 7:10 a.m. May 30, 2014 - PR Newswire - PRF
Clinical Study Results, Schedule of Upcoming Conferences, Dividend Declaration, and Services Agreement - Analyst Notes on Gilead, Quest Diagnostics, Sarepta Therapeutics, Incyte and Centene 5:10 a.m. May 28, 2014 - PR Newswire - PRF
AHF: ‘Negligent Corporate Welfare’ Pushes Gilead to Top of S&P 500 5:40 p.m. May 22, 2014 - BusinessWire - BZX
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF
Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults 5:00 p.m. May 20, 2014 - BusinessWire - BZX
Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology 7:40 a.m. May 20, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the 2014 UBS Healthcare Conference on Tuesday, May 20 5:00 p.m. May 19, 2014 - BusinessWire - BZX
Critical Alerts For Goldman Sachs, Noodles & Company, Starbucks, Gilead Sciences, and Time Warner Cable Released By InvestorsObserver 9:31 a.m. May 14, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14 5:00 p.m. May 13, 2014 - BusinessWire - BZX
Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 4:31 p.m. May 9, 2014 - BusinessWire - BZX
Cancer Diagnostics Partnering Terms and Agreements 5:41 p.m. May 7, 2014 - PR Newswire - PRF
Gilead Announces $5 Billion Share Repurchase Program 5:17 p.m. May 7, 2014 - BusinessWire - BZX
Medivir: a Supplemental New Drug Application Has Been Submitted to the U.S. FDA for Simeprevir in Combination with Sofosbuvir 8:06 a.m. May 7, 2014 - BusinessWire - BZX
Biotech Stocks Review -- Research on Retrophin, Merrimack, Gilead Sciences, and Rexahn Pharma 12:37 p.m. May 6, 2014 - PR Newswire - PRF
BetterInvesting Magazine Releases July Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use 4:15 p.m. May 2, 2014 - PR Newswire - PRF
Parion Sciences Reacquires Rights to Epithelial Sodium Channel Inhibitors 9:00 a.m. April 30, 2014 - PR Newswire - PRF
The World Market for Orphan Drugs 6:59 p.m. April 29, 2014 - PR Newswire - PRF
Critical Alerts For Comcast, Gilead Sciences, Ciena, Adobe Systems, and Celldex Therapeutics Released By InvestorsObserver 9:31 a.m. April 29, 2014 - PR Newswire - PRF
Federal Circuit Rules for Axinn Client Natco Pharma Ltd. in Tamiflu Patent Appeal 1:50 p.m. April 25, 2014 - BusinessWire - BZX
(0)
(0)Scroll down for more posts ▼